On October 25, 2024, Homburger advised Molecular Partners, a clinical-stage biotechnology company, in the announcement of the pricing of an underwritten public offering. The offering consisted of 3,642,988 American Depositary Shares (ADSs), representing new shares, priced at $5.49 per